Palantir stock today: PLTR edges lower as Fed minutes and year-end trading test the AI rally

Palantir stock today: PLTR edges lower as Fed minutes and year-end trading test the AI rally

NEW YORK, December 31, 2025, 12:18 ET — Regular session

  • Palantir shares were down about 0.4% in midday trading, tracking a mild dip in U.S. stocks.
  • Investors are weighing the Fed’s latest meeting minutes and what they signal for 2026 rate cuts.
  • A bullish Wedbush note kept Palantir in focus heading into the New Year.

Palantir Technologies Inc shares were down 0.4% at $180.18 in midday trading on Wednesday, easing alongside a muted pullback in U.S. equities on the final trading day of 2025. The stock has traded between $179.34 and $181.80, with volume around 8.8 million shares.

Palantir has been one of 2025’s standout AI-linked software stocks, up about 140% for the year. Wedbush Securities analyst Dan Ives, who named Palantir a top AI stock pick for 2026, set a $230 price target and said demand for the company’s AI platform remained “unprecedented.” Business Insider

The latest drift lower follows the release of Federal Reserve meeting minutes on Tuesday — the detailed record of policymakers’ discussions — which showed deep divisions over the latest quarter-point rate cut. The minutes pointed to a more cautious policy outlook in 2026, with officials projecting just one additional cut next year.

The S&P 500 ETF SPY was down about 0.2%, while the Nasdaq-tracking QQQ fell about 0.3%. Among AI-related names, Nvidia rose about 0.9% as Snowflake slid about 0.8% and C3.ai dropped about 2.5%.

For Palantir, the focus is less on single-session moves and more on whether growth can keep pace with a valuation shaped by a sharp 2025 run-up.

The Denver-based company sells software used to integrate data and run analytics for governments and businesses. It has also been marketing its Artificial Intelligence Platform, or AIP, to help customers deploy AI tools inside their operations.

In its most recent quarterly update in November, Palantir forecast fourth-quarter revenue of $1.327 billion to $1.331 billion and raised its full-year outlook, citing demand for its data analytics services.

The company has not announced a date for its next earnings report. Wall Street Horizon currently lists February 2, 2026, after the closing bell as an unconfirmed reporting date.

Investors will also be watching the Fed’s next policy meeting, scheduled for January 27-28, as markets test whether easing can continue without a renewed inflation problem.

Rate expectations matter for Palantir and other high-growth software stocks because a larger share of their value rests on profits expected years out, which are worth less when interest rates stay higher.

Traders will be looking for signs of stronger conviction in early January as liquidity returns and big funds reset allocations. Any fresh disclosures around large government work or major enterprise deployments can also move the shares quickly.

For now, PLTR is hovering near $180 into the year-end close, with the next catalysts coming from earnings guidance and the macro backdrop set by the Fed.

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Taiwan Semiconductor

NYSE: TSM 96 / 100
#2 BUY

AerCap

NYSE: AER 95 / 100
#3 BUY ON PULLBACK

Constellation Energy

NASDAQ: CEG 93 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

American International Group

NYSE: AIG 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.
MIAX slides as year-end trading thins — what traders are watching next
Previous Story

MIAX slides as year-end trading thins — what traders are watching next

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing
Next Story

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing